Domestic and foreign cardiac societies recommend SGLT-2 for preserving exudation rates
Forxiga, a blockbuster treatment with an annual prescription of 90 billion won, has expanded its scope to the entire heart failure. AstraZeneca Korea held a press conference at The Plaza Hotel in Jung-gu, Seoul on the 3rd to commemorate the expansion of chronic heart failure indications, including preservation of SGLT-2 inhibitor Forxiga ejection rate. At the meeting, Yoon Jong-chan, a professor of cardiology at Catholic University Seoul St. Mary's Hospital, and Oh Jae-won, a professor of cardiology at Yonsei University Severance Hospital, led by Kang Seok-min, chairman of the Korean Heart Failure Association (Cardiology at Seve